HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bhatia, V Articles by Dhindsa, M Search for Related Content PubMed PubMed Citation Articles by Bhatia, V Articles by Dhindsa, M

Drug-eluting stents: new era and new concerns

¹ Department of Internal Medicine, State University of New York, Buffalo, New York, USA
² SMS Medical College, Jaipur, India

Correspondence to:
Correspondence to:
Dr V Bhatia
Department of Internal Medicine, Mercy Hospital of Buffalo, 565 Abbott Road, State University of New York, Buffalo, NY 14220, USA; vbhatia{at}buffalo.edu

At present there is much excitement about drug-eluting stents, which hold promise for the treatment of coronary artery disease. This ingenious therapy involves coating the outside of a standard coronary stent with a thin polymer containing medication that can prevent scarring at the site of coronary intervention. Early trials with sirolimus coated stents showed that they might prevent coronary artery restenosis, but later studies, involving more complex coronary lesions, did not show a complete absence of restenosis. Recent studies have demonstrated the long term cost effectiveness of drug-eluting stents as they have reduced the need for revascularisation procedures. At present there are few data on the safety and effectiveness of stents over follow up periods exceeding two years, and data obtained from animal models of stenting might not be completely applicable to humans. There are concerns that drug-eluting stents might delay, rather than inhibit, restenosis. Also there is concern regarding the inflammation caused by the polymer substrate. This article reviews the present data on drug-eluting stents and their benefits, shortcomings, and concerns.

Keywords: Drug-eluting stents; coronary stents; sirolimus; paclitaxel

Abbreviations: GP, glycoprotein; IVUS, intravessel ultrasound; PCI, percutaneous coronary intervention; PES, paclitaxel-eluting stent; QCA, quantitative coronary angiogram; QP2, 7-hexanoyltaxol; SES, sirolimus-eluting stents; SMC, smooth muscle cell

This article has been cited by other articles:

				H. Yu, K. Sliedregt-Bol, H. Overkleeft, G. A. van der Marel, T. J.C. van Berkel, and E. A.L. Biessen Therapeutic Potential of a Synthetic Peptide Inhibitor of Nuclear Factor of Activated T Cells as Antirestenotic Agent Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1531 - 1537. [Abstract] [Full Text] [PDF]

				G. T. Jones, I. P. Kay, J.W. S. Chu, G.T. Wilkins, L.V. Phillips, M. McCormick, A.M. van Rij, and M.J.A. Williams Elevated Plasma Active Matrix Metalloproteinase-9 Level Is Associated With Coronary Artery In-Stent Restenosis Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): e121 - e125. [Abstract] [Full Text] [PDF]

				S. G. Raja Drug-Eluting Stents and the Future of Coronary Artery Bypass Surgery: Facts and Fiction. Ann. Thorac. Surg., March 1, 2006; 81(3): 1162 - 1171. [Abstract] [Full Text] [PDF]